603127 昭衍新药
2024/09 - 九个月
人民币(K¥)
2023/12
人民币(K¥)
2022/12
人民币(K¥)
2021/12
人民币(K¥)
2020/12
人民币(K¥)
经营活动产生之现金流量净额192,326622,875971,066685,655428,386
投资活动产生之现金流量净额(950,051)(315,429)(2,160,131)(2,069,807)(254,903)
筹资活动产生之现金流量净额(248,828)(361,678)(99,332)5,290,402(36,874)
汇率变动对现金及现金等价物的影响(6,969)8,41037,470(60,898)(8,523)
现金及现金等价物净增加/(减少)(1,013,523)(45,823)(1,250,927)3,845,352128,086
期初现金及现金等价物余额2,853,6472,899,4704,150,396305,044176,958
期末现金及现金等价物余额1,840,1252,853,6472,899,4704,150,396305,044